Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2018

01-06-2018 | Correction

Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells

Authors: Qi Zhang, Xiao-Ting Li, Yue Chen, Jia-Qi Chen, Jian-Yun Zhu, Yu Meng, Xiao-Qian Wang, Yuan Li, Shan-Shan Geng, Chun-Feng Xie, Jie-Shu Wu, Cai-Yun Zhong, Hong-Yu Han

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Login to get access

Excerpt

Unfortunately, the online published article has error in Fig. 4. The correct Fig. 4 is given here. …
Metadata
Title
Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells
Authors
Qi Zhang
Xiao-Ting Li
Yue Chen
Jia-Qi Chen
Jian-Yun Zhu
Yu Meng
Xiao-Qian Wang
Yuan Li
Shan-Shan Geng
Chun-Feng Xie
Jie-Shu Wu
Cai-Yun Zhong
Hong-Yu Han
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3590-z

Other articles of this Issue 6/2018

Cancer Chemotherapy and Pharmacology 6/2018 Go to the issue

Original Article

Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer

Original Article

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

Original Article

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein

Original Article

Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab

Original Article

A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer

Original Article

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits